Sanofi

With an eye on the FDA, Lexicon and Sanofi line up more positive data on diabetes drug
With an eye on the FDA, Lexicon and Sanofi line up more positive data on diabetes drug
Endpoints
FDA
Lexicon Pharmaceuticals
Sanofi
type 1 diabetes
sotagliflozin
Flag link:
Pharma's giants, new and old, tell more tales than their numbers show
Pharma's giants, new and old, tell more tales than their numbers show
Fierce Pharma
Big Pharma
JNJ
Pfizer
GSK
Roche
Novartis
Sanofi
Bristol-Myers Squibb
Flag link:
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
Fierce Pharma
pharma stocks
Merck
Pfizer
AbbVie
Eli Lilly
Bristol-Myers Squibb
GSK
Roche
Sanofi
Bayer
Novo Nordisk
Celgene
Biogen
AstraZeneca
Flag link:
Sanofi brings another insulin glargine patent suit against Merck
Sanofi brings another insulin glargine patent suit against Merck
Drug Delivery Business News
Sanofi
patents
Merck
insulin glargine
Lantus
Flag link:
Sanofi believes it’s still not too late to become a top player in cancer drug market
Sanofi believes it’s still not too late to become a top player in cancer drug market
Endpoints
Sanofi
oncology
R&D
Flag link:
Sanofi shifts focus to internal R&D as it preps an end to a stunningly effective Regeneron alliance
Sanofi shifts focus to internal R&D as it preps an end to a stunningly effective Regeneron alliance
Endpoints
Sanofi
R&D
Regeneron
drug development
Flag link:
GlaxoSmithKline GLP-1 Tanzeum meets its end, and it doesn't bode well for Sanofi, AstraZeneca: analyst
GlaxoSmithKline GLP-1 Tanzeum meets its end, and it doesn't bode well for Sanofi, AstraZeneca: analyst
Fierce Pharma
GSK
GLP-1 agonist
Tanzeum
Sanofi
AstraZeneca
Flag link:
Vaccines provide a boost for GlaxoSmithKline, Sanofi and Merck in second-quarter financials
Vaccines provide a boost for GlaxoSmithKline, Sanofi and Merck in second-quarter financials
Fierce Pharma
vaccines
GSK
Sanofi
Merck
earnings
Flag link:
Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat
Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat
Fierce Pharma
Sanofi
eczema
Dupixent
drug launches
earnings
Flag link:
Sanofi meets 2Q profit forecasts
Sanofi meets 2Q profit forecasts
Yahoo/AP
Sanofi
earnings
Flag link:
Despite scoring an FDA nod, Merck's biosim Lusduna must wait to challenge Lantus
Despite scoring an FDA nod, Merck's biosim Lusduna must wait to challenge Lantus
Fierce Pharma
FDA
Merck
biosimilars
Lusduna Nexvue
Lantus
diabetes
Sanofi
Hatch Waxman Act
Flag link:
Sanofi offers Ablynx billions of biobucks for nanobody partnership
Sanofi offers Ablynx billions of biobucks for nanobody partnership
Fierce Biotech
Sanofi
Ablynx
nanobodies
R&D
Flag link:
With help from Novartis and Sanofi, NeuroVia heads to the clinic armed with a $14M round
With help from Novartis and Sanofi, NeuroVia heads to the clinic armed with a $14M round
Endpoints
Novartis
Sanofi
NeuroVia
X-ALD
Flag link:
The flu vaccines are coming: GSK, Sanofi ship the first of more than 150M doses headed to U.S.
The flu vaccines are coming: GSK, Sanofi ship the first of more than 150M doses headed to U.S.
Fierce Pharma
GSK
Sanofi
vaccines
flu vaccines
Seqirus
Flag link:
Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent
Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent
Fierce Pharma
payers
Sanofi
Regeneron
eczema
Dupixent
dupilumab
Flag link:
Sanofi gets a flu vaccines booster with $650M-plus Protein Sciences buy
Sanofi gets a flu vaccines booster with $650M-plus Protein Sciences buy
Fierce Pharma
Sanofi
Sanofi Pasteur
M&A
Protein Sciences
flu vaccine
vaccines
Flag link:
Why Drugmakers Aren’t Sweating the Next Wave of Patent Losses
Why Drugmakers Aren’t Sweating the Next Wave of Patent Losses
Bloomberg
patents
Roche
Sanofi
Eli Lilly
patent cliff
Flag link:
Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul
Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul
Bloomberg
rare disease
healthcare reform
Shire
Jazz Pharmaceuticals
Sanofi
Roche
Biogen
Alexion
Vertex Pharmaceuticals
Flag link:
Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug
Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug
Endpoints
Sanofi
Alnylam
clinical trials
fitusiran
hemophilia
Roche
emicizumab
Flag link:
EuroBiotech Report: Brexit, BioNTech success, GlaxoSmithKline inks AI deal, Silence takes Alnylam to court and Shire makes cuts
EuroBiotech Report: Brexit, BioNTech success, GlaxoSmithKline inks AI deal, Silence takes Alnylam to court and Shire makes cuts
Fierce Biotech
Europe
biotech
Brexit
BioNTech
GSK
artificial intelligence
Sanofi
Exscientia
Silence Therapeutics
RNAi
Flag link:

Pages